OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV) OCREVUS SC provides an additional treatment ...

ZURICH, Feb. 24, 2025 /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab) for subcutaneous ...

Sandoz is offering treprostinil injection for subcutaneous administration to treat patients diagnosed with pulmonary arterial hypertension. Sandoz treprostinil injection was the first generic of ...

The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...

Some experts believe offering a subcutaneous version of nivolumab could make PD-1 inhibitors available to new groups of patients who currently lack access, such as those in rural areas. This article ...

A subcutaneous version of the newly approved Alzheimer's drug lecanemab (Leqembi) may be on the horizon. Weekly subcutaneous lecanemab 100 mg/mL injection appeared to be as effective at amyloid plaque ...

Please provide your email address to receive an email when new articles are posted on . Subcutaneous administration of a breast cancer therapy significantly decreased treatment time compared with IV ...

Advances in device technologies and component innovations, such as Datwyler’s NeoFlex™ plungers, facilitate home-based ...

This marks the approval of the first and only subcutaneous immune checkpoint inhibitor in Europe that can be administered by a health care provider in as little as one minute RAHWAY, N.J., November 19 ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...

A novel indwelling subcutaneous intrathecal catheter circumvented the complex spine anatomy of patients with spinal muscular atrophy (SMA), a challenge when giving nusinersen via intrathecal injection ...